Terrana Biosciences

Terrana Biosciences is a US-based biotech firm focused on developing RNA-based agricultural solutions that enhance plant health and resilience against environmental challenges. Terrana Biosciences, founded in 2021 and headquartered in Cambridge, US, specializes in RNA-based innovations for agriculture. The company has completed one funding round, securing USD 50. 00 mn from Flagship Pioneering in July 2025, which will support their ongoing development in crop protection and yield enhancement.

Terrana Biosciences specializes in innovative RNA-based plant health solutions designed to address various challenges in agriculture. Its flagship product offerings leverage a comprehensive RNA platform that integrates nature’s intelligence with machine learning to facilitate plant health from seed to stem. The company's solutions are aimed at tackling issues such as disease prevention, pest management, rapid adaptation to climatic changes, and enhancing soil health. Terrana's product line is targeted toward agricultural stakeholders, including farmers, agronomists, and agricultural research institutions, facilitating improved crop yields and resilience.

The primary markets for these products extend across North America, Europe, and parts of Asia, where the demand for sustainable agricultural solutions is growing. Terrana Biosciences generates revenue through business-to-business transactions, primarily by collaborating with agricultural organizations and research institutions. These partnerships involve providing tailored RNA-based solutions that can be integrated into existing agricultural practices. The company structures its transactions through licensing agreements or direct sales to clients, allowing for customization based on specific regional agricultural needs.

While specific pricing details are not disclosed, the revenue model involves multi-year contracts providing ongoing support and product access, ensuring clients can effectively utilize Terrana’s technologies throughout the growing season. This structure positions Terrana to capitalize on the increasing demand for sustainable agricultural practices in the global market. In July 2025, Terrana Biosciences raised USD 50 mn in venture funding from new investor Flagship Pioneering. The company plans to utilize this funding to scale operations and advance the development of its initial ribonucleic acid-based products for crop protection and yield enhancement.

Furthermore, Terrana aims to expand its market presence in North America, Europe, and Asia by introducing new products designed to meet the evolving demands of sustainable agriculture.